D-0502

Phase 3Small molecule

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

D-0502 is one of 31 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

D-0502

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

3 2

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 3

Tianeptine

Pfizer

Preclinical

1 4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 6

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 7

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Not yet recruiting

Breast Cancer

NCT07336771

Q4 2028

Phase 3Recruiting

Breast Cancer

NCT06954961

Clinical

Trials by Indication[1]

Breast Cancer3 trials

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Not yet recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT07336771·60 enrolled

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Completed·IInventisBio Co., Ltd·Phase 1·NCT03471663·200 enrolled

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Recruiting·IInventisBio Co., Ltd·Phase 3·NCT06954961·640 enrolled

Female1 trial

Evaluation of Relative Bioavailability of D-0502 Tablet in Healthy Female Subjects

Completed·IInventisBio Co., Ltd·Phase 1·NCT05226338·18 enrolled

Unspecified1 trial

Food Effect Study of D-0502 Tablet in Healthy Volunteers

Completed·IInventisBio Co., Ltd·Phase 1·NCT03810625·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for D-0502. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D-0502 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D-0502. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Alphamab Biopharmaceuticals Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu Alphamab Biopharmaceuticals Co., Ltd

D-0502

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Breast Cancer3 trials

Female1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News